New drug cocktail aims to outsmart lung cancer resistance

NCT ID NCT07285148

Not yet recruiting Disease control Sponsor: Beijing Pearl Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, ANS014004 and PLB1004, given together to people with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially after standard treatments stop working. About 253 adults with locally advanced or metastatic disease will take part across two phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ANS014004 (MET inhibitor) and PLB1004 (EGFR inhibitor)
What this could lead to: If successful, this combination could offer a new treatment option for people with EGFR-mutated lung cancer whose tumors have stopped responding to standard therapy.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so the safety and effectiveness are not yet proven. Side effects from the drug combination are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR MUTATION MET ALTERATION METASTATIC LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center David H, Koch Center lor Cancer Care

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.